Baidu
map

Am J Cardiol:伴CABG病史患者的CTO病变 PCI复合方法可行

2014-04-08 高晓方 译 医学论坛网

美国一项研究表明,与不伴冠脉旁路移植术(CABG)病史的患者相比,通过复合方法(“hybrid” crossing algorithm)对伴CABG病史患者的慢性完全闭塞病变实施经皮冠脉介入(CTO PCI)的成功率稍低,但并发症发生率相似。论文于4月2日在线发表于《美国心脏病学杂志》(Am J Cardiol)。 此项研究共纳入496例接受CTO PCI治疗的序贯性患者,并对伴和不伴CABG病

美国一项研究表明,与不伴冠脉旁路移植术(CABG)病史的患者相比,通过复合方法(“hybrid” crossing algorithm)对伴CABG病史患者的慢性完全闭塞病变实施经皮冠脉介入(CTO PCI)的成功率稍低,但并发症发生率相似。论文于4月2日在线发表于《美国心脏病学杂志》(Am J Cardiol)。

此项研究共纳入496例接受CTO PCI治疗的序贯性患者,并对伴和不伴CABG病史的患者进行了转归比较。在伴CABG病史的患者中评估CTO PCI成功率及并发症发生率。

结果显示,与无CABG病史的患者相比,伴CABG病史者年龄较为年长,冠脉疾病风险较高,并且有利基线血管造影CTO特征较少。伴CABG者的技术和操作成功率稍低,更有可能应用逆行方法实施CTO PCI(P<0.001),并且放射暴露量和透视时间更高((P<0.001))。两组患者的严重操作并发症发生率基本相似。

原始出处:


Georgios Christopoulos, Rohan V. Menon, Dimitri Karmpaliotis,Khaldoon Alaswad, William Lombardi, J. Aaron Grantham, Tesfaldet T. Michael, Vishal G. Patel, Bavana V. Rangan, Anna P. Kotsia,  Nicholas Lembo, David Kandzari, James Lee, Anna Kalynych, Harold Carlson,Santiago Garcia, Subhash Banerjee, Craig A. Thompson, Emmanouil S. Brilakis.Application of the “Hybrid Approach” to Chronic Total Occlusions In Patients With Prior Coronary Artery Bypass Graft Surgery (From a Contemporary Multicenter US Registry).The American Journal of Cardiology 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1993674, encodeId=e37b19936e45e, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Thu Nov 13 07:07:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781664, encodeId=0fdc1e8166436, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 14 12:07:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862741, encodeId=81821862e41b8, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Fri Feb 27 21:07:00 CST 2015, time=2015-02-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1993674, encodeId=e37b19936e45e, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Thu Nov 13 07:07:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781664, encodeId=0fdc1e8166436, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 14 12:07:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862741, encodeId=81821862e41b8, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Fri Feb 27 21:07:00 CST 2015, time=2015-02-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1993674, encodeId=e37b19936e45e, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Thu Nov 13 07:07:00 CST 2014, time=2014-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781664, encodeId=0fdc1e8166436, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 14 12:07:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862741, encodeId=81821862e41b8, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Fri Feb 27 21:07:00 CST 2015, time=2015-02-27, status=1, ipAttribution=)]
    2015-02-27 gao_jian4217
Baidu
map
Baidu
map
Baidu
map